Loading stock data…
GDTC
$0.97-0.02 (-2.36%)
Market ClosedLast close May 1
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
CytoMed Therapeutics Limited in the Healthcare sector is trading at $0.97. The stock is currently near its 52-week low of $0.73, remaining 37.6% below its 200-day moving average. Technical signals show neutral RSI of 51 and bearish MACD signal, explaining why GDTC maintains its current current market pressure. The Whystock Score of 35/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 51) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$0.97
Potential Upside
5%
Whystock Fair Value$1.02
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$11.25M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-0.21
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-
Volume
Today's trading volume
15,871
Recent News
CytoMed Therapeutics And 2 More Penny Stocks With Promising Prospects
As February begins, major U.S. stock indexes have shown a robust start, with the Dow Jones Industrial Average and S&P 500 posting significant gains. In such an optimistic market climate, investors often look beyond the well-known giants to explore opportunities in lesser-known areas like penny stocks. Though traditionally associated with high risk, penny stocks can offer intriguing prospects when supported by solid financials. This article will highlight three such companies that may provide...
Cytomed Therapeutics refutes ‘misleading’ claims, reaffirms clinical progress
CytoMed Therapeutics (GDTC) issued a statement to address recent statements containing “inaccurate and misleading” claims regarding the Company’s research programs, clinical progress, and operations.The company said, ” CytoMed categorically rejects such claims which have no basis. Certain statements circulating publicly mis-characterize the Company’s scientific focus, development status, and regulatory standing. Please refer to recent announcements by the Company on our progress. CytoMed’s resea